Trial Profile
Comparable efficacy and safety profiles of daily injection of BK0023 and filgrastim (Neupogen®) in chemotherapy-induced neutropenia: a multinational, multicenter, investigator blind, randomised, parallel group study in women with breast cancer
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2014
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary)
- Indications Neutropenia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bio-Ker
- 03 Nov 2014 New trial record